Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07351045

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Obesity or Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CEDIC Centro de Investigaciones Clinicas, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must have at screening:
  • Body mass index (BMI) greater than or equal to (≥)30.0 kg/m^2; or
  • BMI ≥27.0 kg/m^2 and <30.0 kg/m^2 with at least one weight-related comorbidity, such as prediabetes, hypertension, dyslipidemia, diagnosis of obstructive sleep apnea, or weight-related cardiovascular disease
  • History of ≥1 self-reported unsuccessful diet/exercise effort to lose body weight
  • Ability and willingness to self-administer the study drug (or receive an injection from a trained individual if visually impaired or with physical limitations)

Exclusion criteria

  • History of Type 1 diabetes mellitus (T1DM) or T2DM, or history of ketoacidosis or hyperosmolar state/coma. Prior, but not current, diagnosis of gestational diabetes is allowed if no history of diabetes is recorded since.
  • Self-reported change in body weight >5 kg within 3 months prior to screening
  • Obesity induced by other endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., melanocortin 4 receptor deficiency or Prader-Willi syndrome)
  • Prior or planned surgical treatment for obesity. Liposuction or abdominoplasty if performed more than 1 year prior to screening is allowed.
  • Known clinically significant gastric emptying abnormality (e.g., severe gastroparesis or gastric outlet obstruction)
  • History of acute or chronic pancreatitis or clinically significant gallbladder disease. History of acute pancreatitis caused by gallstones or clinically significant gallbladder disease is allowed if the participant had a cholecystectomy to resolve the problem at least 3 months prior to screening.
  • Poorly controlled hypertension at screening
  • Any of the following cardiovascular conditions within 3 months prior to screening: Acute myocardial infarction; Cerebrovascular accident (stroke)/transient ischemic attack; Unstable angina; Hospitalization due to congestive heart failure.
  • Have a history of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder, or other serious mood or anxiety disorder). Participants with MDD or generalized anxiety disorder whose disease state is considered stable within 1 year prior to screening and expected to remain stable throughout the course of the study, in the opinion of the investigator, are allowed provided that they are not receiving prohibited medication.
  • Treatment with any approved or investigational GLP-1-RA-based therapy (e.g., GLP-1 receptor mono agonist, GLP-1/GIP receptor dual agonist, GLP-1/GIP/Gluc receptor triple agonist) within 6 months prior to randomization

Treatment and study plan

Placebo

Combination Product

Placebo will be volume-matched and administered once weekly using an integrated drug-device combination product.

Enicepatide

Combination Product

Enicepatide will be administered once weekly at the randomized dosing regimen using an integrated drug-device combination product.

Other names: RO7795068, CT-388, RG6640

Primary outcomes

  1. Percent (%) Change from Baseline in Body Weight at Week 72

    Time frame: Baseline through Week 72

Secondary outcomes

  1. Percentage of Participants Achieving ≥5% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  2. Percentage of Participants Achieving ≥10% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  3. Percentage of Participants Achieving ≥15% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  4. Percentage of Participants Achieving ≥20% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  5. Percentage of Participants Achieving ≥25% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  6. Change from Baseline in Body Weight (kg) at Week 72

    Time frame: Baseline through Week 72

  7. Change from Baseline in Waist Circumference (cm) at Week 72

    Time frame: Baseline through Week 72

  8. Change from Baseline in Fasting Glucose at Week 72

    Time frame: Baseline through Week 72

  9. Change from Baseline in Fasting Insulin at Week 72

    Time frame: Baseline through Week 72

  10. Change from Baseline in Low-Density Lipoprotein (LDL) Cholesterol at Week 72

    Time frame: Baseline through Week 72

  11. Change from Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 72

    Time frame: Baseline through Week 72

  12. Change from Baseline in Triglyceride at Week 72

    Time frame: Baseline through Week 72

  13. Change from Baseline in Systolic Blood Pressure at Week 72

    Time frame: Baseline through Week 72

  14. Change from Baseline in the Physical Functioning Domain Score of the Short Form (36) Health Survey Version 2 (SF-36v2) Acute Form at Week 72

    Time frame: Baseline through Week 72

  15. Change from Baseline in Physical Functioning Composite Score of the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire at Week 72

    Time frame: Baseline through Week 72

  16. Change from Baseline in Waist-to-Hip Ratio at Week 72

    Time frame: Baseline through Week 72

  17. Change from Baseline in Waist-to-Height Ratio at Week 72

    Time frame: Baseline through Week 72

  18. Percentage of Participants Achieving Normoglycemia (HbA1c <5.7%) at Week 72

    Time frame: Baseline and Week 72

  19. Change from Baseline in Subscale Scores of the Control of Eating Questionnaire (CoEQ) at Week 72

    Time frame: Baseline through Week 72

  20. Change from Baseline in Symptoms and Impact of Urinary Incontinence as Assessed by the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) at Week 72

    Time frame: Baseline through Week 72

  21. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Change (PGI-C) Urinary Incontinence Questionnaire at Week 72

    Time frame: Baseline and Week 72

  22. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the Patient Global Impression of Severity (PGI-S) Urinary Incontinence Questionnaire at Week 72

    Time frame: Baseline and Week 72

  23. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-C Physical Functioning Questionnaire at Week 72

    Time frame: Baseline and Week 72

  24. Percentage of Participants Experiencing No Change, Improvement, or Worsening on the PGI-S Physical Functioning Questionnaire at Week 72

    Time frame: Baseline and Week 72

  25. Change from Baseline in Health Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Form Domain Scores and Component Summary Scores at Week 72

    Time frame: Baseline through Week 72

  26. Change from Baseline in HRQoL as Assessed by the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire Domain Scores and Total Score at Week 72

    Time frame: Baseline through Week 72

  27. Change from Baseline in Non-HDL Cholesterol at Week 72

    Time frame: Baseline through Week 72

  28. Change from Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 72

    Time frame: Baseline through Week 72

  29. Change from Baseline in Total Cholesterol at Week 72

    Time frame: Baseline through Week 72

  30. Change from Baseline in Free Fatty Acids at Week 72

    Time frame: Baseline through Week 72

  31. Change from Baseline in Diastolic Blood Pressure at Week 72

    Time frame: Baseline through Week 72

  32. Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 72

    Time frame: Baseline through Week 72

  33. Percentage of Participants Achieving ≥30% Body Weight Loss from Baseline at Week 72

    Time frame: Baseline and Week 72

  34. Change from Baseline in Body Mass Index (BMI) at Week 72

    Time frame: Baseline through Week 72

  35. Percent (%) Change from Baseline in Body Weight by Obesity Class at Week 72

    Time frame: Baseline through Week 72

  36. Time to Achieve ≥5%, ≥10%, ≥15%, ≥20%, ≥25%, ≥30% Body Weight Loss from Baseline Through Week 72

    Time frame: From Baseline through Week 72

  37. Change from Baseline in Total Lean Tissue Volume (Litres) at Week 72, as Assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Baseline through Week 72

  38. Percent (%) Change from Baseline in Total Lean Tissue Volume at Week 72, as Assessed by MRI

    Time frame: Baseline through Week 72

  39. Change from Baseline in Total Adipose Tissue Volume (Litres) at Week 72, as Assessed by MRI

    Time frame: Baseline through Week 72

  40. Percent (%) Change from Baseline in Total Adipose Tissue Volume at Week 72, as Assessed by MRI

    Time frame: Baseline through Week 72

  41. Incidence and Severity of Adverse Events, with Severity Determined According to Mild/Moderate/Severe Criteria

    Time frame: Baseline through Week 72

  42. Change from Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score Through Week 72

    Time frame: Baseline through Week 72

  43. Change from Baseline in the Patient Health Questionnaire-9 (PHQ-9) Score Through Week 72

    Time frame: Baseline through Week 72

Study contacts

Contact information is provided by the study sponsor or research team.

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

CONTACT

Reference Study ID Number: WC45725 https://forpatients.roche.com/ No attachments to email below.

CONTACT

[email protected]

888-662-6728 (U.S. Only)

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Acronym: Enith1

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Jan 20, 2026
Registry last updated
Jul 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.